Kornimate/medical-research-clean huggingface dataset:
the burden of multiple myeloma on patients and caregivers quality of life: a canadian real-world study

Conditions: Multiple Myeloma; Caregiver Subjective Burden; Quality of Life (QOL)

Summary: the purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of qol. additionally, this study will assess the correlation between qol, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.

potential participants will be identified by myeloma canada using their database. myeloma canada is a registered non-profit organization created by, and for, canadians impacted by multiple myeloma. as part of myeloma canada website, patients and caregivers can subscribe to a mailing list to receive their monthly newsletter and to participate in surveys. this database comprises about 5,000 individuals, including patients and caregivers. an e-mail will be sent to 600 patients and 200 caregivers randomly selected to invited them to participate in the survey. interested participants will be invited to visit the participant portal on the proxy website (https://periproxy.com/en), to sign the informed consent form and complete online questionnaires. upon request, paper-based documents (i.e., informed consent form and questionnaires) can also be sent by mail. the following questionnaires will be used: patients * patient information questionnaire (i.e., baseline characteristics) * eortc qlq-c30 * eortc qlq-my20 * eq-5d-5l * esas-r * patients perspective caregivers * caregiver information questionnaire (i.e., baseline characteristics) * cargoqol * caregivers perspective if the sample size (i.e., 300 patients and 100 caregivers) is not reached one month after the first e-mail, an invitation e-mail will be sent to an additional 600 eligible patients and/or 200 caregivers randomly selected. this scheme of participant identification will be performed until the sample size is reached.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older; 2. part of the myeloma canada database; 1. identified as a patient with mm or 2. identified as a current caregiver of a patient with mm at the time of participation. 3. ability to read and understand english or french; 4. signature of informed consent form (icf). exclusion criteria: no exclusion criteria

Keywords: quality of life real-world observational myeloma caregiver
comparison between pupillometry and the numerical rating scale

Conditions: Pain, Acute

Summary: given the difficulties encountered with subjective pain assessment tools, one of the ideas for reducing the occurrence of insufficient analgesia administration in the emergency department is to find a tool capable of measuring pain without requiring the patient's participation, and which could be integrated into the systematic measurement of the 4 other vitals. an interesting idea is the measurement of pupillary diameter and its reflex variations by a portable pupillometer. indeed, the diameter of the pupil (dp) reflects the constant interactions between the sympathetic and parasympathetic systems at the level of the iris muscles. pupillometry measures the change in pupillary diameter and allows the performance of three dynamic tests useful in the assessment of pain.


Eligibility criteria:
inclusion criteria: * all patients presenting to the emergency room, aged 18 years or over, able to communicate, with hemodynamic and respiratory stability, are eligible. exclusion criteria: * - refusal to participate in the study; refusal to sign informed consent. * consent impossible to obtain (cognitive disorders, language barrier...). * patient taking immediate-release opioid medication (last dose within the last 12 hours). * patient taking prolonged-release opioid medication (last dose within the last 24 hours). * basic treatment with a dopaminergic d2 antagonist (antipsychotic drugs). * basic treatment with dopamine antagonist antiemetic medication (metoclopramide (t1/2 5-6h), domperidone (t1/2 7-9h), alizapride (t1/2 3h)) within the last 12 hours. * patient taking clonidine (last dose within the last 24 hours). * use of topical ocular drugs modifying pupillary parameters in the last 24 hours. * bilateral eye surgery modifying the possibilities of variation in pupillary diameter bilaterally. * parkinson's or alzheimer's disease at a dysautonomic stage. * admission to the emergency room for acute ocular pathology. * history of diabetes at a dysautonomic stage. * history of alcoholism at a dysautonomic stage. * history of glaucoma. * pregnant patient with preeclampsia.

Keywords: pupillometry
the use of functional electrical stimulation in conjunction with respiratory muscle training to improve unaided cough in individuals with acute spinal cord injury

Conditions: Acute Spinal Cord Injury

Summary: the overall objective of this study is to improve unaided cough with abdominal and latissimus dorsi functional electrical stimulation in conjunction with respiratory muscle training in individuals with acute spinal cord injuries.


Eligibility criteria:
inclusion criteria: 1. traumatic and atraumatic c2- t12 spinal cord injury (ais a, b, and c motor incomplete and complete injuries) currently admitted to inpatient rehabilitation with an injury date \< 12 months prior to enrollment 2. positive response to electrical stimulation through a palpable contraction 3. fluent in written and spoken english exclusion criteria: 1. individuals who do not meet inclusion criteria 2. prisoners 3. concurrent traumatic brain injury determined by rancho level of cognitive functioning \< vi 4. individuals with open tracheostomy 5. persons with pacemakers 6. pregnant women 7. persons with epilepsy 8. open wounds or metal implants at site of electrode placement 9. unresponsive to functional electrical stimulation 10. current diagnosis or history of thoraco-abdomino-pelvic cancer
intraperitoneal bupivicaine infusion using the on-q pain pump after laparoscopic surgery

Conditions: Postoperative Pain

Summary: after laparoscopic surgery most patients experience some form of mild to moderate pain. the current standard of care is to treat this pain with local anesthetics (numbing medication, that deadens the nerve endings) to the small surgical incisions (cuts) and narcotic systemic analgesics (medication injected into your vein to control pain such as morphine). although this treatment improves pain symptoms it is not perfect. firstly, complete pain control is rarely achieved and secondly, narcotics (such as morphine) often have many side effects including nausea, vomiting, sedation (sleepiness), constipation and abdominal upset. all of these issues make recovery less comfortable and delays return to full function (work, school and other activities of daily life). a new fda approved device is now available that offers the benefits of long term anesthesia without the side effects of narcotics. it consists of a pump that continuously infuses local anesthesia into and around the surgical site. this pump is placed during your operation. you then carry a tennis ball sized container made of soft plastic in a pouch which drips numbing medicine around your wounds for 2 days continuously. the purpose of this study is to see if this pump improves postoperative pain, decreases the need for narcotic pain medicine and allows people to return to their activities earlier.

the procedure of the current study is to randomly assign patients undergoing minimally invasive surgeries (laparoscopic cholecystectomies and laparoscopic lap-banding procedures) to one of two groups. both groups will have the standard surgical procedure performed and then at the completion will have the on-q system placed in a subdiaphragmatic (within the abdomen) location. half of the study group will have bupivicaine, a numbing medicine in the pump while the other half will have sterile saline in their pump. neither the patient nor the surgeon will be aware of which group any particular patient is in, this is a process known as "blinding" and improves the reliability of the results. all patients will receive the standard locally infiltrated trocar site local anesthetic and either a prescription for vicodin for ambulatory patients or morphine injected into their vein for patients staying in the hospital. all patients will then be asked at preset intervals their level of pain the presence of nausea and their need for vicodin or morphine. ambulatory patients will be reached by phone for answers to these questions. all patients will have their pain controlled in the usual and standard way at all times. the on-q pump will be removed at 48hours. the results will then be statistically reviewed to see if the on-q pumps were of benefit.

Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic cholecystectomy or lap-band asa iii or less exclusion criteria: * patients who refuse consent * are converted from laparoscopy to open surgery * are allergic to bupivacaine * are unable to followup
bioequivalence between we 941 od and brotizolam (lendormin®) taken with water in healthy adult males

Conditions: Healthy

Summary: the bioequivalence of we 941 od tablets prepared in oral disintegrating tablet form and brotizolam conventional tablets (lendormin® tablets), both taken with water, was evaluated in healthy adult male subjects.


Eligibility criteria:
inclusion criteria: * age between 20 and 35 years * weight between 50 and 80 kg * obesity level within the range of +/- 20% of the standard weight according to the body mass index (bmi) method * judged as eligible as a study object following the screening test by the investigator * volunteers to participate in the study, who are capable of giving written informed consent exclusion criteria: * known hypersensitivity to drugs * history of drug or alcohol abuse * received other investigational drug within 4 months of the trial drug administration * had \> 400 ml of whole blood drawn within 3 months of the trial drug administration * had \> 400 ml of blood components drawn within 1 month of the trial drug administration * used any drug within 10 days of the trial drug administration * engaged in strenuous exercise within 5 days of the trial drug administration * consumed alcohol within 3 days of the trial drug administration * judged as ineligible for the study participation by the investigator for a reason other than above
a dose escalation phase i study of pdc-1421 capsule targeting in depression

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the safety of pdc-1421 capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive effect.

outcome measures: physical examination, vital sign, electrocardiograph (ecg), hematology, blood chemistry, aes/saes monitoring and columbia-suicide severity rating scale (c-ssrs)

Eligibility criteria:
inclusion criteria: 1. aged 20-65 years. 2. subjects must be able to understand and willing to sign informed consent. 3. female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later after ending of study. 4. laboratory data: red blood cell count(rbc),white blood cell count(wbc), platelets, hematocrit, hemoglobin, prothrombin time(pt), partial thromboplastin time (aptt),aspartate transaminase(ast),alanine aminotransferase(alt), lactate dehydrogenase(ldh), total bilirubin, blood urea nitrogen(bun),serum creatinine, free thyroxine (ft4), thyroid-stimulating hormone (tsh) level,sodium, potassium, calcium, glucose, are all within the normal range. 5. no significantly abnormal findings on physical examination, ecg and vital sign. exclusion criteria: 1. with any clinically significant neurological, gastrointestinal, renal, hepatic,cardiovascular, respiratory, metabolic, endocrine, hematological or other major disorders as determined by the investigator. 2. a positive drug screen. 3. any mental disorder diagnosed by board-certificated psychiatrist through detailed diagnostic interview. 4. any history of suicidal behavior in the past 6 months when evaluated by the c-ssrs. 5. the intensity of suicidal ideation in the past 6 months is no less than 4 defined by the c-ssrs. 6. have received any prescribed medicine, investigational drug or any non prescribed medicine (including herbal remedies) with 14 days prior to enroll this study.

Keywords: major depressive disorder depression
incretin hormone antagonism after bariatric surgery

Conditions: Bariatric Surgery

Summary: using the glucagon-like peptide-1 (glp-1) antagonist exendin(9-39) and the glucose-dependent insulinotropic peptide (gip) antagonist gip(3-30), the purpose of this study is to clarify the importance of endogenous glp-1 and gip for postprandial glucose metabolism after rygb and sg in subjects with normal glucose tolerance. we hypothesize that glp-1 is more important after rygb, and gip is more important after sg, for postprandial glucose tolerance and beta-cell function. a group of un-operated subjects with normal glucose tolerance will serve as controls.


Eligibility criteria:
inclusion criteria, surgery groups: * age \> 18 years * rygb or sg operation \> 12 months prior to inclusion * weight stable (± 3 kg during the last month) * hba1c \< 48 mmol/mol before surgery, and no history of diabetes * hba1c \< 48 mmol/mol and fasting plasma glucose \< 6.1 mmol/l at inclusion inclusion criteria, control group: * age \> 18 years * no former rygb- or sg operation * weight stable (± 3 kg during the last month) * hba1c \< 48 mmol/mol, fasting plasma glucose \< 6.1 mmol/l and no history of diabetes exclusion criteria: * thyrotoxicosis or inadequately treated hypothyreosis * hemoglobin \< 6.5 mmol/l at inclusion * pregnancy or breast feeding * medication affecting the planned examinations matching between groups * age * sex * bmi at inclusion and for surgery groups also pre-surgery bmi

Keywords: glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide roux-en-y gastric bypass sleeve gastrectomy gastric bypass bariatric surgery glucose diabetes exendin(9-39) gip(3-30)
evolution of the survival of patients with sezary syndrome (ss) over the 1998-2020 period and its association with the early use of therapeutic monoclonal antibodies

Conditions: Sezary Syndrome; Cutaneous T Lymphoma

Summary: sezary syndrome (ss) is a rare, aggressive and advanced form of cutaneous t lymphoma with a poor prognosis (5-year survival rate varying between 24% and 52%). the treatments are only suspensive with short-term remissions. for the past fifteen years, therapeutic approaches have been based on depleting monoclonal antibodies (anti-cd52, anti-ccr4, anti-kir3dl2, anti-cd70), or antibody-drug conjugates (anti-cd30). but while the efficacy of mogamulizumab on progression-free survival was reported in the phase iii study, no study on a large cohort has compared the current overall survival of patients with sezary syndrome to that before the era of monoclonal antibodies. in this context, we propose to report a large series of patients with sézary syndrome in order to compare the current survival of patients with that of the pre-monoclonal antibodies era (1998-2003). the objective of this study is to assess the evolution of the overall survival of patients with sezary syndrome since the early use of therapeutic monoclonal antibodies. the underlying hypothesis of this study is that the use of therapeutic monoclonal antibodies has improved the prognosis of these patients. patients included in this retrospective study are patients with a sezary syndrome diagnosed between 1998 and 2020.


Eligibility criteria:
inclusion criteria: 1. adult patients over 18 years of age 2. patient with sezary syndrome diagnosed between 1998 and 2020 exclusion criteria: 1. patient opposition to research 2. patient under guardianship or curatorship, unable to express opposition
periodontal status in fermented food and food consumption

Conditions: Periodontal Diseases

Summary: lack of certain nutrients and foods may negatively affect oral health. therefore, nutrition plays an important role in maintaining oral health. this study aimed to evaluate and compare the nutrient intakes, consumption of food groups and some fermented foods of individuals with periodontal disease and health. ninety-three patients who applied to periodontology clinic were divided into three groups: periodontal health, gingivitis and periodontitis. in addition, plaque, gingival indices, bleeding on probing, periodontal pocket depth, and clinical attachment level were evaluated. to determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.


Eligibility criteria:
inclusion criteria: * patients with three teeth other than 20-year-old teeth in each jaw exclusion criteria: * pregnancy and lactation, * patients with an acute oral lesion or necrotizing ulcerative periodontitis, - * patients with history of diabetes, rheumatic fever, lung and kidney disorders, and use of drugs that affect periodontal tissues (regular use of antibiotics, anti-inflammatory and mouthwashes), * patients who smoke, or patients who did not quit until last year were not included in the study.

Keywords: fermented foods periodontal health periodontal disease
the effect of acupressure and reiki on pain and fatigue levels

Conditions: Acupressure; Cancer Pain; Fatigue

Summary: this research was conducted with the aim of determining the effect of levels of pain and fatigue of acupressure and reiki application on cancer patients receiving palliative care. the research was a single-blind, repeated measures, randomized controlled study. research data were collected between february and july 2022. the research sample consisted of acupressure and reiki application groups and a control group with 52 patients in each group, a total of 156 patients. data was collected by means of a patient description form, an analgesic follow-up form, the eastern cooperative oncology group performance status scale, the numeric pain rating scale, and the brief fatigue inventory.


Eligibility criteria:
inclusion criteria: 1. having a diagnosis of third or fourth-stage cancer, 2. being aged 18 years or older, 3. having had pain for at least one month in connection with cancer treatment or the symptoms of the disease, 4. using nsaii or non-opioid analgesics, 5. having a status of 3 or more on the numeric pain rating scale (nprs), 6. having a score of 0-3 on the ecog-ps scale exclusion criteria: 1. having a diagnosis of first or second-stage cancer, 2. being aged less than 18 years, 3. having bone or brain metastasis, 4. using opioid analgesics, 5. having a status of less than 3 on the nprs, 6. having a status of between 4 and 5 on the ecog-ps scale
safety and immunogenicity study of live attenuated vaccine against herpes zoster in chinese adults aged 50 years and older

Conditions: Herpes Zoster

Summary: this study evaluates the safety and immunogenicity of live attenuated vaccine in adults aged 50 years and older. half of participants will receive high doses of the vaccine,while the other half will receive low doses of the vaccine in phase i clinical trial. at the phase ii clinical trial, participants will be distributed equally to four groups(low、middle, high doses of the vaccine and placebo).


Eligibility criteria:
inclusion criteria: * adults 50 years and older,no vaccine contraindications; * subject to comply with the requirements of clinical trial programs; * no immune globulin vaccination history within a month, no vaccination history within 28 days; * axillary temperature ≤37.0 ℃; * patients with chronic diseases should be in stable ; * postmenopausal or female subjects is no longer the possibility of pregnancy, or subjects pregnancy test was negative and has no pregnancy planner during the clinical trial period; * the value of blood routine (wbc, rbc, hb) is normal , or abnormal but meaningless by clinicians judgment ; * alanine aminotransferase (alt) values is normal, or abnormal but meaningless by clinicians judgment ; * renal function (serum urea nitrogen) is normal, or abnormal but meaningless by clinicians judgment. exclusion criteria: * allergies, seizures, epilepsy, encephalopathy and other medical history or family history of mental illness; * subjects who is allergic to any element of the vaccine,and have a history of severe allergy to any vaccine; * subjects who is suffering from immune deficiency, receiving immunosuppressive therapy or immunocompromised due to hiv; * subjects who had a history of herpes zoster five years ago; * varicella or herpes zoster vaccination history; * pregnant or lactating women; * women who are planning a pregnancy in the near future; * any prior administration of vaccine in last 28 days or planned to vaccinate any vaccine during the observation period; * suffering from acute febrile diseases, and infectious diseases; * thrombocytopenia or other coagulation disorder history, which may cause subcutaneous taboo; * accept any other investigational drug users within two months; * subjects had high fever (axillary temperature ≥38.0 ℃) in the past three days ; * the value of blood routine (wbc, rbc, hb) is abnormal and meaning by clinicians judgment ; * alanine aminotransferase (alt) values is abnormal and meaning by clinicians judgment ; * renal function (serum urea nitrogen) is abnormal and meaning by clinicians judgment. * blood pressure is abnormal after medication control; * known or suspected diseases including: respiratory diseases, acute infection or chronic disease , and cardiovascular disease, kidney disease, skin disorders in the acute phase; * any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.

Keywords: vaccine safety immunogenicity
endogenous opioid modulation by ketamine

Conditions: Major Depressive Disorder

Summary: demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.

this study will test the hypothesis that the rapidly-acting antidepressant ketamine improves core depressive symptoms by acutely activating the brain's endogenous µ-opioid system.

Eligibility criteria:
inclusion criteria: * age 18-65 * dsm-5 major depressive disorder * current moderate-to-severe, treatment-resistant, depressive episode * patient health questionnaire (phq-9) total score ≥ 10 * phq-9 item score ≥ 2 on "little interest or pleasure" item * phq-9 item score ≥ 2 on "feeling down, depressed, or hopeless" item * medical documentation of depression for at least 2 months * inadequate response to at least one adequate antidepressant medication trial in the current episode exclusion criteria: * current episode duration \>5 years * moderate-to-severe dsm-5 substance use disorder (past year) * cognitive disorder (past year) * post-traumatic stress disorder (past year) * obsessive compulsive disorder (past year) * personality disorder (past year) * positive urine drug screen * psychotic symptoms * mania * significant neurologic disorder or injury * breastfeeding or pregnancy * imminent suicide risk * current use of cyp3a4 inhibitors (e.g., ketoconazole or erythromycin) * other unstable psychiatric or medical condition requiring a higher level of care * contraindication to ketamine, mri, or pet